The use of acetylcholinesterase inhibitors (DP, RSM, GAL) and/or the non-competitive inhibitor of NMDAR (memantine) and anti-amyloid monoclonal antibodies (aducanumab and lecanemab) in dementia and AD, would be able to contribute to the temporary improvement or consolidation of the losses of memory and other cognitive functions, to the decline of behavioral disorders, and to limiting the patient’s dependence on aids; at the same time, however, these agents can bring great discomfort through the multitude of adverse reactions [147]. Here, GAL is linked to Alzheimer disease.